AbbVie Inc. (ABBV) income statement
NYSE · Healthcare · Drug Manufacturers - General · 57,000 employees · CEO Robert A. Michael
- Price
- $294.89 +1.41%
- Market cap
- $521B
- Enterprise value
- $585B
- Last report
- Q3 '26 filed 2026-09-30
- Next report
- 2027-02-03 EPS est. $3.90
AbbVie Inc. (ABBV) reported revenue of $17.4B for Q3 '26 (+10.3% year on year), operating income of $6.48B (37.3% of revenue) and net income of $4.22B. Over the last four quarters revenue was $66B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3B | $12.3B | $14.5B | $14.5B | $15.1B | $13.3B | $15.4B | $15.8B | $16.6B | $15B | $17B | $17.4B | |
| Cost of revenue | $5.7B | $4.09B | $4.2B | $4.21B | $4.4B | $4B | $4.35B | $5.3B | $4.55B | $4.22B | $4.29B | $2.62B | |
| Gross profit | $8.6B | $8.22B | $10.3B | $10.2B | $10.7B | $9.34B | $11.1B | $10.5B | $12.1B | $10.8B | $12.7B | $14.8B | |
| Research & development | $2.21B | $1.94B | $1.95B | $2.13B | $6.77B | $2.07B | $2.13B | $2.32B | $2.58B | $2.47B | $2.34B | $2.57B | |
| Other operating expenses | $0 | $164M | $937M | $82M | $1.57B | $248M | $799M | $2.68B | -$217M | $0 | $291M | $1.65B | |
| Operating expenses | $5.4B | $5.42B | $6.26B | $6.42B | $12.2B | $5.61B | $6.18B | $8.57B | $6.26B | $6.05B | $6.27B | $8.31B | |
| Operating income | $3.2B | $2.8B | $4B | $3.83B | -$1.49B | $3.73B | $4.89B | $1.9B | $5.81B | $4.73B | $6.43B | $6.48B | |
| Interest income | $186M | $207M | $220M | $129M | $92M | $73M | $62M | $72M | $59M | $72M | $67M | $0 | |
| Interest expense | $564M | $660M | $726M | $720M | $702M | $700M | $740M | $739M | $714M | $717M | $746M | $700M | |
| Other non-operating income (gains on investments, FX ...) | $1.42B | $383M | $1.13B | $1.03B | $77M | $1.37B | $2.6B | $451M | $2.43B | $2.98B | -$291M | $0 | |
| Total non-operating income | -$1.98B | -$1.04B | -$1.85B | -$1.75B | -$779M | -$2.07B | -$3.34B | -$1.19B | -$3.14B | -$3.7B | -$2.15B | -$1.65B | |
| Income before tax | $1.21B | $1.76B | $2.15B | $2.08B | -$2.27B | $1.66B | $1.55B | $714M | $2.67B | $1.04B | $4.28B | $4.83B | |
| Income tax | $388M | $383M | $773M | $520M | -$2.25B | $372M | $613M | $526M | $853M | $342M | $662M | $609M | |
| Net income | $822M | $1.37B | $1.37B | $1.56B | -$22M | $1.29B | $938M | $186M | $1.82B | $699M | $3.61B | $4.22B | |
| EPS (basic) | $0.46 | $0.77 | $0.77 | $0.88 | -$0.02 | $0.72 | $0.53 | $0.10 | $1.02 | $0.39 | $2.04 | $2.38 | |
| EPS (diluted) | $0.46 | $0.77 | $0.77 | $0.88 | -$0.02 | $0.72 | $0.53 | $0.10 | $1.02 | $0.39 | $2.04 | $2.38 | |
| Shares (basic, weighted) | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | |
| Shares (diluted, weighted) | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | |
| Depreciation & amortization | $2.08B | $2.07B | $2.13B | $2.08B | $2.1B | $2.04B | $2.05B | $2.06B | $1.99B | $1.94B | $1.88B | $0 | |
| EBITDA | $3.85B | $4.49B | $5B | $4.88B | $535M | $4.4B | $4.34B | $3.52B | $5.37B | $3.69B | $8.61B | $6.48B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.6B | $28.2B | $32.8B | $33.3B | $45.8B | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B | |
| Cost of revenue | $5.83B | $7.04B | $7.72B | $7.44B | $15.4B | $17.4B | $17.4B | $20.4B | $16.9B | $18.2B | |
| Gross profit | $19.8B | $21.2B | $25B | $25.8B | $30.4B | $38.8B | $40.6B | $33.9B | $39.4B | $43B | |
| Research & development | $4.59B | $5.33B | $10.8B | $6.79B | $7.76B | $8.05B | $6.51B | $7.68B | $12.8B | $9.1B | |
| Other operating expenses | $0 | $0 | $500M | -$890M | $0 | $432M | $753M | $599M | $2.75B | -$241M | |
| Operating expenses | $10.5B | $11.6B | $18.7B | $12.8B | $19.1B | $20.8B | $22.5B | $21.1B | $30.3B | $22.9B | |
| Operating income | $9.34B | $9.55B | $6.38B | $13B | $11.4B | $17.9B | $18.1B | $12.8B | $9.14B | $20.1B | |
| Interest income | $82M | $146M | $204M | $275M | $174M | $39M | $186M | $540M | $648M | $266M | |
| Interest expense | $1.05B | $1.15B | $1.35B | $1.78B | $2.45B | $2.42B | $2.23B | $2.22B | $2.81B | $2.89B | |
| Other non-operating income (gains on investments, FX ...) | $409M | $668M | -$162M | $2.77B | $5.51B | $2.51B | $2.41B | $4.28B | $2.61B | $10.6B | |
| Total non-operating income | -$1.46B | -$1.82B | -$1.19B | -$4.56B | -$7.97B | -$4.94B | -$4.64B | -$6.51B | -$5.42B | -$13.5B | |
| Income before tax | $7.88B | $7.73B | $5.2B | $8.43B | $3.4B | $13B | $13.5B | $6.25B | $3.72B | $6.6B | |
| Income tax | $1.93B | $2.42B | -$490M | $544M | -$1.22B | $1.44B | $1.63B | $1.38B | -$570M | $2.36B | |
| Net income | $5.95B | $5.31B | $5.69B | $7.88B | $4.62B | $11.5B | $11.8B | $4.86B | $4.28B | $4.23B | |
| EPS (basic) | $3.65 | $3.31 | $3.69 | $5.30 | $2.73 | $6.48 | $6.65 | $2.73 | $2.40 | $2.37 | |
| EPS (diluted) | $3.63 | $3.30 | $3.68 | $5.28 | $2.72 | $6.45 | $6.63 | $2.72 | $2.39 | $2.37 | |
| Shares (basic, weighted) | 1.62B | 1.6B | 1.54B | 1.48B | 1.67B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | |
| Shares (diluted, weighted) | 1.63B | 1.6B | 1.55B | 1.48B | 1.67B | 1.78B | 1.78B | 1.77B | 1.77B | 1.77B | |
| Depreciation & amortization | $1.19B | $1.5B | $1.77B | $2.02B | $6.47B | $8.52B | $8.47B | $8.7B | $8.39B | $8.14B | |
| EBITDA | $10.1B | $10.4B | $8.31B | $12.2B | $12.3B | $23.9B | $24.2B | $17.2B | $14.9B | $17.6B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-01